Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome

TY - JOUR

T1 - Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome

AU - Iversen, Kasper K

AU - Dalsgaard, Morten

AU - Teisner, Ane S

AU - Schoos, Mikkel

AU - Teisner, Borge

AU - Nielsen, Henrik

AU - Grande, Peer

AU - Clemmensen, Peter

N1 - Copyright 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: To examine if pregnancy-associated plasma protein-A (PAPP-A) in patients with chest pain, could identify patients at risk for death or myocardial infarction. Design and methods: Patients admitted with chest pain and both normal ECG and normal biomarkers were evaluated by serial measurement of PAPP-A. Main outcome measures were mortality and non-fatal myocardial infarction. Results: Median age of patients included (415) was 67. years and 43% were women. The risk of death or non-fatal myocardial infarction after 3 months was 15% in the highest quartile of circulating PAPP-A compared with 3% in the lowest quartile (relative risk 3.7, p< 0.01). Corresponding numbers after 1 year were 24% and 10% (relative risk 2.4, p= 0.01). Conclusion: In patients admitted with chest pain and both normal ECG and normal biomarkers PAPP-A seems to be valuable for predicting patients at high risk of death or non-fatal myocardial infarction.

AB - Objectives: To examine if pregnancy-associated plasma protein-A (PAPP-A) in patients with chest pain, could identify patients at risk for death or myocardial infarction. Design and methods: Patients admitted with chest pain and both normal ECG and normal biomarkers were evaluated by serial measurement of PAPP-A. Main outcome measures were mortality and non-fatal myocardial infarction. Results: Median age of patients included (415) was 67. years and 43% were women. The risk of death or non-fatal myocardial infarction after 3 months was 15% in the highest quartile of circulating PAPP-A compared with 3% in the lowest quartile (relative risk 3.7, p< 0.01). Corresponding numbers after 1 year were 24% and 10% (relative risk 2.4, p= 0.01). Conclusion: In patients admitted with chest pain and both normal ECG and normal biomarkers PAPP-A seems to be valuable for predicting patients at high risk of death or non-fatal myocardial infarction.

U2 - 10.1016/j.clinbiochem.2010.03.018

DO - 10.1016/j.clinbiochem.2010.03.018

M3 - Journal article

SN - 0009-9120

VL - 43

SP - 851

EP - 857

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 10-11

ER -